Spotlight on Lamotrigine in Bipolar Disorder

CNS Drugs

Volumn 18, Issue 1, 2004, Pages 63-67

  Goldsmith, David R ^a   Wagstaff, Antona J ^a   Ibbotson, Tim ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Bipolar Depression; Bipolar Disorder; Bodyweight Gain; Lamotrigine; Valproate Semisodium

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; VALPROATE SEMISODIUM; ANTIDEPRESSANT AGENT; TRIAZINE DERIVATIVE;

ARTICLE; BIPOLAR DISORDER; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; INFECTION; INSOMNIA; NAUSEA; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; RASH; STEVENS JOHNSON SYNDROME; TREATMENT DURATION; TREMOR; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; DRUG INTERACTION; DRUG TOLERANCE; LONGITUDINAL STUDY; METABOLISM; TIME; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; HUMANS; LONGITUDINAL STUDIES; TIME FACTORS; TREATMENT OUTCOME; TRIAZINES;

EID: 1442354104     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/00023210-200418010-00007     Document Type: Article

References (47)

1. Goa KL, Ross SR, Chrisp P, et al. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46(1): 152–76
2. Li X, Ketter TA, Frye MA. Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? J Affect Disord 2002 May; 69(1–3): 1–14
3. Fitton A, Goa KL. Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 1995 Oct; 50: 691–713
4. 2+ currents in cortical neurons: functional implications. Eur J Pharmacol 1996; 307: 113–6
5. Wang S-J, Huang C-C, Hsu K-S, et al. Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones. Neuroreport 1996; 7: 3037–40
6. von Wegerer J, Hesslinger B, Berger M, et al. A calcium antagonistic effect of the new antiepileptic drug lamotrigine. Eur Neuropsychopharmacol 1997 May; 7(2): 77–81
7. Siniscalchi A, Zona C, Guatteo E, et al. An electrophysiological analysis of the protective effects of felbamate, lamotrigine, and lidocaine on the functional recovery from in vitro ischemia in rat neocortical slices. Synapse 1998 Dec; 30(4): 371–9
8. Leach MJ, Baxter MG, Critchley MAE, et al. Neurochemical and behavioral aspects of lamotrigine. Epilepsia 1991; 32Suppl 2: S4–8
9. Rataud J, Debarnot F, Mary V, et al. Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents. Neurosci Lett 1994; 172: 19–23
10. Shuaib A, Mahmood RH, Wishart T, et al. Neuroprotective effects of lamotrigine in global ischemia in gerbils. A histological, in vivo microdialysis and behavioral study. Brain Res 1995; 702: 199–206
11. Smith SE, Meldrum BS. Cerebroprotective effect of lamotrigine after focal ischemia in rats. Stroke 1995; 26: 117–22
12. Wiard RP, Dickerson MC, Beek O, et al. Neuroprotective properties of the novel antiepileptic lamotrigine in a gerbil model of global cerebral ischemia. Stroke 1995; 26: 466–72
13. w-nitro-L-arginine methyl ester of motoneuron cell death after neonatal axotomy. Neuroscience 1996; 71(2): 313–25
14. Schulz JB, Matthews RT, Henshaw DR, et al. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience 1996; 71(4): 1043–8
15. Adams J, Collaço-Moraes Y, de Belleroche J, et al. Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J Neurochem 1996; 66: 6–13
16. Prescribing information: Lamictal® (lamotrigine) [online]. Available from URL: http://us.gsk.com/products/assets/us_lamictal.pdf [Accessed 2003 Jun 25]
17. 1 receptor mediated response in rat brain. Neurochem Int 2002 Apr; 40(4): 315–9
18. Culy CR, Goa KL. Lamotrigine: a review of its use in childhood epilepsy. Paediatr Drugs 2000 Jul; 2(4): 299–330
19. Xie X, Hagan RM. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology 1998 Oct; 38(3): 119–30
20. Smith D, Chadwick D, Baker G, et al. Seizure severity and the quality of life. Epilepsia 1993; 34Suppl. 5: S31–5
21. Smith D, Baker G, Davies G, et al. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993; 34(2): 312–22
22. Jacoby A, Baker G, Bryant-Comstock L, et al. Lamotrigine add-on therapy is associated with improvement in mood in patients with severe epilepsy [abstract no. I.4]. Epilepsia 1996; 37 Suppl. 5: 202
23. Cohen AF, Ashby D, Crowley G, et al. Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam. Br J Clin Pharmacol 1985; 20: 619–29
24. Ginsberg L, Sachs G, KetterT, et al. Effects of mood stabilizers on body weight in bipolar I disorder [abstract no. NR463 plus poster]. American Psychiatric Association 2003 Annual Meeting — new research abstracts; 2003 May 17–22; San Francisco (CA), 173–4
25. Yuen WC, Peck AW. Lamotrigine pharmacokinetics: oral and i.v. infusion in man. Proceedings of the British Pharmacological Society; 1988 Apr 6–8. Br J Clin Pharmacol 1988; 26(2): 242P
26. Garnett WR. Lamotrigine: pharmacokinetics. J Child Neurol 1997 Nov; 12Suppl. 1: S10–5
27. Cohen AF, Land GS, Breimer DD, et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987; 42: 535–41
28. Ramsay RE, Pellock JM, Garnett WR, et al. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilep Res 1991; 10: 191–200
29. Meyer FP, Banditt P, Schubert A, et al. Lamotrigine concentrations in human serum, brain tissue, and tumor tissue. Epilepsia 1999 Jan; 40: 68–73
30. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993; 25(6): 433–43
31. Berry DJ. The disposition of lamotrigine throughout pregnancy [abstract no. 90]. Ther Drug Monit 1999 Aug; 21: 450
32. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000 Jun; 41: 709–3
33. Posner J, Holdich T, Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharm Med 1991; 1: 121–8
34. Chen C, Veronese L, Yin Y. The effects of lamotrigine on the pharmacokinetics of lithium. Br J Clin Pharmacol 2000 Sep; 50(3): 193–5
35. Anderson GD, Yau MK, Gidal BE, et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 1996 Aug; 60: 145–56
36. Böttiger Y, Ståhle L. Lamotrigine drug interactions in a TDM material [abstract no. 84]. Ther Drug Monit 1997 Oct; 19: 568
37. Edelbroek PM, Segers JP, Gilissen KGPM, et al. Population pharmacokinetics of lamotrigine to evaluate interaction with concommitant antiepileptic drugs. Epilepsia 1996; 37 Suppl. 4: 64
38. Hossain M, Chen C, Ette E. Characterization of lamotrigine (LTG) drug interactions using the population approach [abstract no. 3148]. Pharm Res 1997 Nov; 14(11 Suppl.): S515
39. May TW, Rambeck B. Influence of oxcarbazepine and methsuximide on LTG concentrations [abstract]. Epilepsia 1998; 39 Suppl. 2: 25
40. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psych 2003; 64(9): 1013–24
41. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003 Apr; 60(4): 392–400
42. Calabrese JR, Bowden CL, Fieve R, et al. Lamotrigine or lithium in the maintenance treatment of bipolar I disorder [abstract no. P.1.115 plus poster]. Presented at the 15th Congress of the European College of Neuropsychopharmacology; 2002 Oct 5–9; Barcelona. Eur Neuropsychopharmacol 2002; 12Suppl. 3: S217
43. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999 Feb; 60(2): 79–88
44. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000 Dec; 20(6): 607–14
45. GlaxoSmithKline, 2003. (Data on file)
46. Bowden CL, Asnis GM, Ginsburg LD, et al. Safety and tolerability of lamotrigine for bipolar disorder. 2003 (Data on file)
47. Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 2002 Nov; 63(11): 1012-9